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Background: Radiation dermatitis is common in patients treated with combined radiotherapy and chemotherapy
for head and neck malignancies. Its timely and adequate management is of uttermost importance for both
oncological outcomes and global quality of life. We prospectively evaluated the role of hypericum perforatum
and neem oil (Holoil®; RIMOS srl, Mirandola, Italy) in the treatment of acute skin toxicity for patients undergoing
radiotherapy or chemo-radiotherapy for head and neck cancer.
Methods: A consecutive series of 28 head and neck cancer patients submitted to radiotherapy (RT) was enrolled
onto this mono-institutional single-arm prospective observational study. Patients undergoing both definitive
or post-operative radiotherapy were allowed, either as exclusive modality or combined with (concomitant or
induction) chemotherapy. We started Holoil treatment whenever bright erythema, moderate oedema or patchy
moist desquamation were observed. Holoil® was used during all RT course and during follow up time, until acute
skin toxicity recovery.
Results: The maximum detected acute skin toxicity was Grade 1 in 7% of patients, Grade 2 in 68%, Grade 3 in 25%,
while at the end of RT was Grade 0 in 3.5%, Grade 1 in 32%, Grade 2 in 61%, Grade 3 in 3.5%. For patients having
G2 acute skin toxicity, it mainly started at weeks 4-5; for those having G3, it began during weeks 5-6. Median times
spent with G2 or G3 toxicity were 17.5 and 11 days. Patients having G2 acute skin toxicity had a dermatitis worsening in
27% of case (median occurrence time: 7 days). G3 events were reconverted to a G2 profile in all patients (median time:
7 days). Those experiencing a G2 skin event were converted to a G1 score in 23% of cases (median time: 14 days).
Time between maximum acute skin toxicity and complete skin recovery after RT was 27 days.
Conclusions: Holoil® proved to be a safe and active option in the management of acute skin toxicity in head and neck
cancer patients submitted to RT or chemo-radiotherapy. A prophylactic effect in the prevention of moist desquamation
may be hypothesized for hypericum and neem oil and need to be tested within a prospective controlled study.
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Radiation dermatitis is a frequent occurrence in patients
undergoing radiotherapy (RT) for head and neck malignan-
cies [1]. Its adequate and timely management is of
paramount importance as it may impact patients adherence
to treatment protocol, with a consequent eventual effect on
clinical outcomes and global quality of life. Acute skin
toxicity generally appears within a few weeks from the start
of radiation, with clinical manifestations varying from mild
erythema to brisk moist desquamation and, rarely, to
ulceration and necrosis [1]. Several factors may potentially
affect skin toxicity characteristics in terms of intensity,
duration and recovery time. Some of them are related to
RTcharacteristics such as total dose, fractionation, radiation
energy and volume of treated regions. Others are patient’s
specific depending on age, eventual comorbid conditions,
skin phototype and genetic predisposition [2]. The addition
of standard chemotherapy and/or biological agents might
consistently increase the toxicity profile [3,4]. At present,
there is no standard approach for the prevention and
treatment of radiation-induced skin toxicity. Several medi-
cations have been proposed in this context such as topical
agents, dressings and advanced medications. Holoil® is a
medical compound made of hypericum flowers (Hyperi-
cum perforaturm) and neem oil (Azadirachta indica)
extracts. Hypericum perforatum has been demonstrated to
have anti-inflammatory properties [5]. Neem oil has
cicatrizing and anti-inflammatory effects [6]. We herein
report on a prospective observational study investigating
the use of Holoil® (RIMOS s.r.l., Mirandola, Italy) as a
local treatment for acute skin toxicity in patients under-
going radiotherapy or chemo-radiotherapy for head and
neck malignancies.
Material and methods
Between November 2013 and June 2014, we enrolled a
consecutive series of 28 patients affected with head and
neck cancer and submitted to RT onto this single-arm
prospective observational study designed to investigate the
potential role of Hypericum perforatum and Neem oil in
the treatment of acute skin toxicity during radiation.
Written informed consent was obtained from all patients.
Inclusion criteria included age > 18 and indication to RT as
definitive treatment or as an adjuvant approach after radical
surgery to the primary site. Patients receiving neck dis-
section and/or neck irradiation were enrolled as well as
those submitted to combined modality treatment (induc-
tion and/or concurrent chemotherapy). Due to specific
peculiarities in terms of skin toxicity, patients undergoing
RT and cetuximab were excluded [7-9].
Treatment strategies
Surgical approaches to the primary tumor and cervical
lymphnodes varied according to the sites of presentationand eventual neck involvement, including partial or total
laryngectomy, partial or emi- glossectomy, pharyngect-
omy, oral cavity excisions with partial mandibulectomies.
Neck dissection, whenever needed, was always perfomed
‘en bloc’ with the excision of the primary sites, specifically
radical or functional, bilateral or monolateral strictly
depending on the clinical assessment of the nodal status
of the neck at diagnosis. RT, either definitive or adjuvant,
was delivered with an ‘intensity-modulated’ approach
(IMRT), employing an Elekta 6 MV linear accelerator
delivering volumetric IMRT (VMAT) (Elekta, Stockholm,
Sweden). For definitive radiation, a ‘simultaneous inte-
grated boost’ approach was used, with the macroscopic
disease receiving 70 Gy/35 fractions (2 Gy daily), an ‘inter-
mediate risk volume’ getting 63 Gy/35 fractions (1.8 Gy
daily) and a ‘low risk volume’ receiving 54.25 Gy/35
fractions (1.55 Gy daily). Post-operative SIB-based RT
generally included a ‘high risk volume’ (60–64 Gy 30–32
fractions; 2 Gy daily) and a low-risk volume (51.2-54.4 Gy;
1.6-1.8 Gy daily). For the post-operative setting, RT started
no longer than 8 weeks from surgery. Image guided radio-
therapy (IGRT) was employed for all treatments monitoring
set up and interfraction motion with a daily cone-beam
computed tomography (CBCT). Chemotherapy was given
as induction treatment using the TPF regimen (Docetaxel
75 mg/m2 and Cisplatin 100 mg/m2 of body surface area on
day 1 and 5-Fluorouracil 1000 mg/m2 of body surface are
as a 24-hours continuous infusion on days 2–5) every
3 weeks or the Carboplatin (AUC 6) +Taxol (175 mg/m2
body surface area) on day 1 every 3 weeks regimen.
Concurrent chemotherapy was given with weekly Cis-
platin (30 mg/m2 body surface area) or weekly Carbo-
platin (AUC 2) for 6–7 weeks.
Clinical assessment
Medical evaluation during IMRT consisted of a weekly clin-
ical evaluation with a visual examination of the neck region
skin performed by the physician in charge of the patient and
a consequent physician-rated score of acute skin toxicity.
The RTOG⁄EORTC toxicity scale was used as reference [10].
Non-skin toxicities were also assessed and managed during
clinical assessment but are not object of this report. After
the end of treatment patients were evaluated up to 90 days
to evaluate and score skin toxicity. Oncological follow up
continued over time according to our institutional proto-
col. The primary end-point of the study was the evaluation
of the activity of Holoil® in the management of ≥G2 acute
skin toxicity in patients undergoing radiation or chemo-
radiation for head and neck cancer. No patient-reported
outcome measures have been analysed.
Acute skin toxicity management
All patients were given a moisturizing cream by the time
of RT first fraction. They were instructed to carefully apply
Table 1 Patients and treatment characteristics
N (%)
Sex
Male 24 (86)
Female 4 (14)
Age
Mean 56.8
Range 31-78
Comorbidities
Diabetes 1 (3.5)
Heart failure 5 (18)
Tumor site
Oral cavity 8 (28.5)
Nasopharynx 1 (3.5)
Oropharynx 11 (39.5)
Hypopharynx 1 (3.5)
Larynx 6 (21.5)
Salivary glands 1 (3.5)
Hystology
SCC 27 (96.5)
Adenoid cystic 1 (3.5)
Grading
G1 2 (7)
G2 8 (28.5)
G3 13 (46.5)
NA 5 (18)
RT setting
Definitive RT 14 (50)
Adjuvant RT 14 (50)
Highest prescribed dose
70 Gy 13 (46.5)
68 Gy 2 (7)
64 Gy 8 (28.5)
60 Gy 5 (18)
Combination therapy
Neoadjuvant CT
TPF x 3 5 (18)
CBDCA + TAX x 3 4 (14)
Concurrent CT
Weekly CDDP 14 (50)
Weekly CBDCA 8 (28.5)
None (exclusive RT) 6 (21.5)
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before treatment session. Moreover patients were pro-
hibited to use other creams or cosmetic products in the
irradiated areas. No topical medications were prescribed
prophylactically. All patients were educated to deterge the
irradiated area only with a specific oil soap and to
generally wear loose clothes. Holoil® ointment was started
whenever bright erythema or moderate oedema or
patchy moist desquamation were observed (G2 acute
skin toxicity according to RTOG scoring scale). Con-
comitantly, moisturizing cream application was inter-
rupted. Generally, for erythema and/or oedema the gel
preparation was employed. For patchy moist desquam-
ation, the oil preparation, with a higher concentration of
active ingredients, was administered. Holoil® was used up
to the end of RT and afterwards during follow up time,
until complete recovery from acute skin toxicity. Twice a
day applications were mostly given.
Results
Patients were mainly male (86%) with a mean age of
56.8 (range 31–78). Tumors were mostly located within
the larynx (21.5%), oral cavity (28.5%) and oropharynx
(39.5%), with a squamous cell histology (96.5%) and a high
tumor grade (46.5%). Radiation therapy was delivered as
definitive (50%) or adjuvant (50%) treatment with pre-
scribed doses ranging from 60 Gy to 70 Gy. Exclusive RT
was delivered in 21.5% of patients. Up to 78.5% of patients
underwent combination therapy with concurrent chemo-
radiation (weekly cisplatin or carboplatin), while 32% of
them were submitted to induction chemotherapy (3 TPF
cycles or 3 cycles of carboplatin + taxol) prior to exclusive
RT or concomitant chemo-radiotherapy. See Table 1 for
detailed patients and treatment characteristics. In the ob-
servation period we submitted 28 patients (55%) to Holoil®
treatment because of ≥G2 acute skin toxicity over a total
cohort of 51 patients examinated at our Department
(23 patients with G0-G1 acute skin toxicity – 45%).
Acute skin toxicity
The maximum detected acute skin toxicity was Grade 1 in
7% of patients, Grade 2 in 68%, Grade 3 in 25%. Con-
versely, the toxicity profile at the end of RT was Grade 0
in 3.5% of patients, Grade 1 in 32%, Grade 2 in 61%,
Grade 3 in 3.5% (see Table 2). For the 26 patients
experiencing G2 acute skin toxicity, these events mainly
started between treatment weeks 4–5; for those having G3
acute skin toxicity (7 patients), this event mainly began
during weeks 5 and 6. Median time spent with a G2 or G3
toxicity during RT was 17.5 and 11 days, respectively
(Table 3). Those patients having a G2 acute skin toxicity
had a worsening of their dermatitis in 27% of case, with a
median occurrence time of 7 days after G2 toxicity obser-
vation. However, G3 events were reconverted to a G2profile in 100% of patients after a median time of 7 days.
Those experiencing a G2 skin event were converted to a
G1 score in 23% of cases after a median time of 14 days.
Time between maximum acute skin toxicity detected
Table 2 Acute skin toxicity rates
Maximum
detected
Treatment
end
Acute skin toxicity Grade Patients (%) Patients (%)
No change over baseline 0 0 (0) 1 (3.5)
Follicular, faint or dull erythema/
epilation/dry desquamation/
decreased sweating
1 2 (7) 9 (32)
Tender or bright erythema,
patchy moist desquamation/
moderate edema
2 19 (68) 17 (61)
Confluent, moist desquamation
other than skin folds, pitting
edema
3 7 (25) 1 (3.5)
Ulceration, hemorrage, necrosis 4 0 0 (0)
Table 4 Acute skin toxicity evolution
Toxicity conversion rate
G2 to G3 7/26 (27%)
Mean time 7 days
G3 to G2 7/7 (100%)
Mean time 7 days
G2 to G1 6/26 (23%)
Mean time 14 days
Time from Max to G0 toxicity
Mean 27 days
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was, meanly, 27 days. See Table 4 for details. Treatment
breaks occurred in 5/28 patients (17.8%) with a median
duration time of 3 days and were due to acute mucositis
occurrence. Globally, 4/5 treatment breakdowns occurred
in the chemo-radiation group (2 patients undergoing
post-operative and 2 definitive radio-chemotherapy).
The remaining patients was submitted to exclusive
post-operative RT. No treatment discontinuation occurred
due to skin toxicity. No adverse effects after Holoil®
administration were observed.Table 3 Acute skin toxicity timeline
Pts (%)
Time to G2 acute skin toxicity
Week 2 1 (3.5)
Week 3 2 (7)
Week 4 8 (28.75)
Week 5 8 (28.75)
Week 6 4 (14.25)
Week 7 3 (10.75)
No G2 events 2 (7)
Time to G3 acute skin toxicity
Week 4 1 (3.5)
Week 5 3 (10.75)
Week 6 3 (10.75)
No G3 events 21 (75)
Days
Time spent with G2 acute skin tox (26 pts)
Mean 17.5
Range 7-40
Time spent with G3 acute skin tox (7 pts)
Mean 11
Range 7-14Discussion
Acute skin toxicity is a common event in patients submit-
ted to RT, particularly whenever combination therapies
are undertaken. Several predisposing factors have been
described to influence the frequency and intensity of skin
reactions in patients undergoing radiation therapy. Some
of them are specifically related to RT characteristics such
as total dose, fraction size, technique, type and energy of
radiation, treatment volume and eventual use of bolus
material [1]. Others include the use of combination ther-
apy with chemotherapy or other medical radiosensitizers
or photosensitizers. Host factors are of paramount import-
ance and include genetic predisposition (Ataxia teleangiec-
tasia, Fanconi’s anemia, Bloom’s syndrome), pre-exisitng
connective tissue and/or autoimmune disorders (sclero-
derma, systemic lupus erythematosus), basal skin con-
ditions, nutritional status, age, comorbidities, smoking,
sun exposure, chrono-aging, photo-aging, phototype
[11]. Different scoring scales have been employed to
classify the spectra of clinical presentations of radiation
dermatitis by several organizations and cooperative
groups such as the National Cancer Institute (NCI), the
Radiation Therapy Oncology Group (RTOG), the European
Organization for Research and Treatment of Cancer
(EORTC), the World Health Organization (WHO). The
most frequently used within available clinical studies are
the RTOG scale and the NCI Common Toxicity Criteria
for Adverse Effects (CTCAE). Most of the scales are based
on a physician-rated assessment and have no correlation
with symptoms experienced by patients, and their impact
of Quality of Life and Activities of Daily Living (ADL). This
may be a pitfall as it may underestimate global conse-
quences of skin toxicity. Radiation dermatitis occurring in
patients receiving concomitant RTand cetuximab, is known
to have different pathophysiological and clinical characteris-
tics and thus has a different scoring scale [12]. At present,
no standard approach exist for the prevention and treat-
ment of radiation and chemo-radiation induced skin le-
sions. Several topical agents have been proposed during the
years. Dressings and advanced medications are considered
extremely useful and can be used to protect the
Figure 1 Acute skin toxicity during concomitant chemo-radiation. Moist skin desquamation on the right lateral lower neck region in a patient
undergoing concurrent radiochemotherapy occurring during the 4th week of treatment (a,b,c). Partial wound healing after 2 weeks treatment with
Holoil on the 6th week of treatment (d).
Figure 2 Recovery from acute skin toxicity after Holoil treatment. Partial wound healing after 2 weeks treatment with Holoil on the
6th week of treatment (a). Complete wound healing with ‘restitutio ad integrum’ 2 weeks after the end of radiochemotherapy (b,c,d).
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case of moist desquamation to control pain, bleeding
and exudate formation. The protection of ulcerated
regions may be obtained with hydrocolloids films.
Interestingly, ultrathin films can be maintained during
RT course, but should be removed whenever saturated
with exudate [13]. Hydrofibers, calcium alginate dress-
ings, polyurethane or silicone foams are helpful when-
ever exudate is abundant. In general, dressings and
advanced medications are extremely expensive for both
patients and healthcare providers and not necessarily
easily manageable on an outpatient basis, often requir-
ing nursing assistance. Thus, all topical agents able to
reduce or delay the need for advanced medications are
regarded with increasing interest. In this sense, hyperi-
cum perforatum is known worldwide as Saint John’s Wort
because it is thought to blossom on Midsummer Day (also
named St John’s Day). It is a flowering plant of the genus
Hypericum used for decades to treat depression or
somatoform disorders [14]. It has also been proposed as
an anticancer agent with a pro-apoptotic action in tumor
cellular coltures and an in vivo inhibition capacity towards
metastases [15-17]. Hyperforin, the major constituent of
hypericum, was also demonstrated to inhibit in-vivo
neo-vascularization processes in an experimental mur-
ine tumor model as to influence in-vitro several key steps
of angiogenesis, such as endothelial cell proliferation,
differentiation and invasion as well as MMP-2 and
urokinase-mediated extracellular matrix degradation [18].
Hypericum perforatum was recently shown to have also
anti-inflammatory and anti-bacterical properties [4].
Neem oil is a vegetable oil obtained by cold extraction
from berries of Azadirachta indica, an evergreen tree
endemic to the Indian subcontinent. Neem extracts
have been used for centuries as cosmetic and as cica-
trizing, bacteriostatic and anti-inflammatory agent in
the traditional folklore Indian medicine, being also in-
cluded in the Ayurvedic Pharmacopoeia India [6,19].
The anti-inflammatory properties of neem oil are due
to the presence of a limonoid (epoxyazadiradione),
which acts on several macrophage migration inhibitory
factors [20]. Holoil® (RIMOS s.r.l., Mirandola, Italy) is a
mixture of hypericum and neem extracts with con-
sistent effects on fibrin reduction and granulation
improvement [21]. It is available in commerce as oil,
gel or gauze pads. This medical compound has been
shown to improve foot wounds with exposed bones in a
patient with bilateral advanced diabetic ulcers [20]. It is
consistently able to manage and potentially cure open
wounds. Our pivotal experience seems to confirm these
properties even in the setting of radiation-induced
acute skin toxicity in head and neck cancer patients
undergoing radiotherapy or chemo-radiotherapy. To
test the hypothesis that Holoil® would be effective inthe management of acute skin lesions, we employed a
reactive approach, rather than a prophylactic one, using
this medical product only at the time of dermatitis oc-
currence, in order to observe, score and follow up skin
events. Whenever a G2 event occurred, we applied
Holoil® as gel (erythema and oedema) or oil formulation
(moist desquamation). Patient’s compliance was con-
sistent, with no particular complaints or difficulties. A
total of 26 patients experienced a G2 acute skin tox-
icity, mainly during weeks 4 and 5 of RT, for a median
duration time of 17.5 days. Those G2 events were con-
verted to a lower score (G1) during RT with a 26% rate,
after a mean time of 14 days. Conversely, 7 patients
had a G3 acute skin toxicity, coming from a previous
G2 condition. These events, mainly occurring during
weeks 5 and 6 of RT, meanly lasted 11 days and were
promptly converted to a lower score (G2 or less) with a
100% rate after a mean time of 7 days. A consistent dis-
crepancy between G3 rate as maximum detected acute
toxicity during RT (25%) and the same rate at the end of
treatment (3.5%) was observed. These findings suggest
that hypericum and neem oil may be active in the
treatment of moist desquamation with a very effective
profile and a very rapid timeline (see Figures 1 and 2
for a clinical example). Interestingly, no patients re-
quired advanced medications, which is a surprising
finding for a subset of patients mainly receiving chemo-
therapy (78.5%) and high-dose radiation (68–70 Gy:
53.5%). In conclusion Holoil® proved to be safe and ac-
tive in the management of acute skin toxicity in head
and neck cancer patients submitted to radiotherapy or
chemo-radiotherapy. Given these data as background, a
prophylactic effect in the prevention of moist desquamation
may be hypothesized for hypericum and neem oil and is
going to be tested within a phase II randomized trial which
is planned in the near future in our Institution.
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